SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddys Laboratories board recommends final dividend

19 May 2022 Evaluate

Dr Reddys Laboratories has informed that the Board of Directors of the Company at its meeting held on May 19, 2022, has recommended a final dividend of Rs 30 (600%) per equity share of Rs 5 each for the financial year 2021-22. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 38th Annual General Meeting (AGM).

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Labs. Share Price

1350.00 21.65 (1.63%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: